Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of “Moderate Buy” from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $57.25.

A number of brokerages have commented on HALO. TD Cowen initiated coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective on the stock. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $48.00 to $51.00 in a report on Friday, June 7th. Benchmark boosted their price objective on Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. JMP Securities reduced their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a research report on Monday.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 109,755 shares in the company, valued at $5,488,847.55. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 30,000 shares of company stock worth $1,338,800. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of the business. Advisors Asset Management Inc. boosted its stake in Halozyme Therapeutics by 0.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock worth $1,742,000 after purchasing an additional 287 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares during the period. FCF Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 1.9% during the first quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 391 shares in the last quarter. New York State Teachers Retirement System lifted its stake in Halozyme Therapeutics by 0.4% in the 1st quarter. New York State Teachers Retirement System now owns 113,820 shares of the biopharmaceutical company’s stock valued at $4,630,000 after acquiring an additional 400 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its position in Halozyme Therapeutics by 0.3% during the 1st quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company’s stock worth $6,748,000 after acquiring an additional 436 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Down 0.8 %

Shares of NASDAQ HALO opened at $52.00 on Thursday. Halozyme Therapeutics has a 12-month low of $32.83 and a 12-month high of $53.00. The firm’s 50-day simple moving average is $44.76 and its 200 day simple moving average is $40.30. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44. The company has a market cap of $6.62 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 0.53 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The company had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. On average, research analysts expect that Halozyme Therapeutics will post 3.66 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.